Is palmitoyl hexapeptide-12 FDA-approved, and what does the research show?

What is palmitoyl hexapeptide-12?

Palmitoyl hexapeptide-12 is an ingredient of cosmetic products applied to the skin ¹. It is not a wellness, weight or performance peptide. The papers and the safety report cited here describe it as a skin-care ingredient, and none as an injection ⁴,⁹,¹,⁵,⁶,⁷,⁸.

A peptide is a short chain of amino acids, the building blocks of proteins. This one is six amino acids long: valine, glycine, valine, alanine, proline and glycine, written VGVAPG ¹. The sequence repeats in elastin, a protein with a key role in the skin's elasticity ⁴,¹. The ingredient is made in a laboratory by joining that chain to palmitic acid, a fatty acid ¹. A 2025 laboratory paper says palmitoylated peptides have shown greater skin permeation than unmodified peptides ⁴.

An ingredient list may still say "palmitoyl oligopeptide." That name was retired because, in the words of a 2014 safety report, it "was vague and indeterminately represented two other ingredients" ¹. The two are this peptide and palmitoyl tripeptide-1 ¹. The old name gave no peptide sequence, a point the report's expert panel "deemed critical to a declaration of safety" ¹. The report studied the peptide inside two trade-name mixtures: Biopeptide EL holds 100 parts per million of it, and Dermaxyl holds 200 ¹.

Is palmitoyl hexapeptide-12 FDA-approved?

No. Palmitoyl hexapeptide-12 is not FDA-approved as a drug: Drugs@FDA lists no approved palmitoyl hexapeptide-12 product as of November 9, 2026 ³. It is a cosmetic ingredient, and cosmetics follow different rules ². The law, FDA says, "does not require cosmetic products and ingredients, other than color additives, to have FDA approval before they go on the market" ².

Safety is the duty of those who make or sell cosmetics. FDA says: "Companies and individuals who manufacture or market cosmetics have a legal responsibility to ensure the safety of their products" ². Neither the law nor FDA's regulations "require specific tests to demonstrate the safety of individual products or ingredients" ². The law also does not require companies to share their safety information with FDA, its page says ².

FDA can order a recall in one circumstance, under the Modernization of Cosmetics Regulation Act of 2022 ¹⁰. The agency must determine that there is "a reasonable probability that a cosmetic is adulterated or misbranded and the use of or exposure to the cosmetic will cause serious adverse health consequences or death" ¹⁰. FDA then "has the authority to order a mandatory recall if the responsible person refuses to do so voluntarily" ¹⁰. The responsible person is the manufacturer, packer or distributor named on the label, who must also report serious adverse events to FDA ¹⁰.

FDA's two cosmetics pages cited here do not agree on recalls. The page on the Act is current as of October 29, 2026 ¹⁰. The page on FDA's authority over cosmetics, current as of November 18, 2025, says "FDA is not authorized to order recalls of cosmetics" ². The authority page's text dates from 2005, updated in 2013; the Act, signed December 29, 2022, gave FDA mandatory recall authority over cosmetics ²,¹¹.

What a product is sold to do decides how the law classes it. The law defines cosmetics by their intended use, the authority page says ². A product "intended for a therapeutic use, such as treating or preventing disease, or to affect the structure or function of the body" is a drug or, in some cases, a medical device ². That holds, the page adds, "even if it affects the appearance" ².

See the FDA status of every peptide, updated weekly.

How does palmitoyl hexapeptide-12 work?

Two mechanisms are proposed, and both rest on laboratory work. The first is a signal to cells. VGVAPG is counted among the matrikines, fragments of the skin's structural proteins that are proposed to act as signals to cells ⁴,⁹.

Shown in cells, by the safety report's summary: the sequence without its fatty acid attracted fibroblasts, which produce collagen and elastin, and monocytes, a type of white blood cell ¹. The fibroblasts in that test came from fetal calf ligament, and the monocytes from human blood ¹. The report's table lists the same finding under palmitoyl hexapeptide-12 ¹. The table heads that row palmitoyl hexapeptide-12, but its result names the "VGVAPG hexapeptide," and its cited study is titled on the bare sequence ¹.

The same report lists two more cell findings ¹. The sequence stimulated human skin fibroblasts to express the precursor of collagenase-1, a collagen-cutting enzyme ¹. It also raised the release of elastase, an elastin-cutting enzyme, from human white blood cells ¹. Both tests used the sequence without its fatty acid, which the report calls hexapeptide-12 ¹.

The second proposed mechanism is mechanical. A 2025 laboratory study proposed that the peptide may act "without involving biogenesis" ⁴. In plain words, it would work as a material, not by making cells produce anything.

In the study's skin tests, its molecules were detected joined to calcium, which the authors read as the start of gel formation ⁴. In laboratory mixtures it also bound to collagen and to hyaluronic acid, a water-holding molecule of the skin ⁴. No study cited here tested either mechanism in living people.

What does the research show?

For the peptide by itself: shown in donated human skin, not in living people. The 2025 study worked on skin removed from donors, and its permeation, drying and staining tests each used skin from a single donor ⁴.

In the permeation test, a 1 percent solution of the peptide sat on a skin sample for eight hours ⁴. The peptide passed through the stratum corneum, the skin's outer layer, into the epidermis beneath it ⁴. The authors estimate that single molecules traveled more than about 100 micrometers, a tenth of a millimeter, into the epidermis ⁴. Calcium-linked assemblies were located up to 80 micrometers below the outer layer ⁴.

The drying tests looked first at water loss. Samples of the outer layer were stripped of their natural fats, which makes them dry out faster ⁴. Stripped samples treated with a 0.45 percent peptide solution lost water more slowly, close to the pace of normal samples ⁴. They lost water more slowly than untreated stripped samples; the figure legend calls the reduction significant, and the paper says every experiment ran at least in triplicate ⁴.

The second drying test measured stress, the tension that builds in the outer layer as it dries and shrinks; a lower figure means less tension. In stripped samples treated with water, the stress ended at 13.1 megapascals, a unit of pressure ⁴. It ended at 1.4 megapascals with the peptide and 0.8 with 5 percent glycerol, a common moisturizing ingredient ⁴. The peptide and glycerol results did not differ significantly, and each group held three to five samples ⁴. Peptide-treated samples did end stiffer than glycerol-treated ones ⁴.

The staining test looked at elastin. Skin with its cells removed was soaked for five days in a peptide solution or in a salt solution ⁴. The peptide-soaked skin stained more heavily for elastin ⁴. With no cells left to make new elastin, the authors read this as the peptide binding to existing fibers ⁴.

These conditions are not a cream's. The permeation test used a 1 percent solution, while the highest concentration the 2014 report found reported in products was 0.002 percent ⁴,¹. Four of the study's 14 authors give The Estée Lauder Companies as their affiliation ⁴. The paper lists support from the AO Foundation, the UK Medical Research Council and the NIHR Nottingham Biomedical Research Centre ⁴. Its authors declare no competing financial interest ⁴.

In people, the published studies cited here include two randomized trials, reported in one 2026 paper, of a finished serum, Regenerating Skin Nectar (ALASTIN Skincare, Inc.) ⁵. The serum holds this peptide and a second palmitoyl peptide with arnica flower extract, soybean oil, panthenyl triacetate "and other botanicals," in amounts the paper calls "proprietary" ⁵. Each trial ran for 14 days after a skin procedure: a fractional carbon dioxide laser in 26 adults, and radiofrequency microneedling, needles that heat the skin, in 25 ⁵. The paper counts 51 subjects completing the trials; laser-trial subjects also used the serum for two weeks beforehand, and four were excluded from the efficacy analysis ⁵.

Each subject used the serum on one half of the face; the other half got only a basic moisturizer, which the serum half also got after day 3 ⁵. The moisturizer is a different product and not the serum without its peptides ⁵.

The dermatologist who graded the skin did not know which half got the serum, but the subjects did ⁵. On the main measure, graded redness, both halves improved and the difference between them "did not reach statistical significance" in either trial ⁵. After the paper's adjustment for repeated comparisons, the serum half recovered significantly more on four measures in the laser trial and one in the microneedling trial ⁵. In the laser trial these were water loss at day 3 and swelling, camera-measured redness and roughness at day 14; in the other, swelling at day 7 ⁵. At day 14, 81.8 percent of the laser-trial subjects analyzed and all microneedling-trial subjects rated the serum half as recovering better ⁵.

The paper states: "Both studies were funded by Galderma" ⁵. It says three of its 15 authors "are employees of Galderma and may hold stock or other financial interests in the company" ⁵. The authors call the trials "exploratory studies with modest sample sizes and no formal sample size calculation" ⁵. Neither Regenerating Skin Nectar trial measured wrinkles or skin elasticity, and a result of either belongs to the serum, not to this peptide alone ⁵. Also cited here are two unpublished skin-tolerance patch tests of a mixture containing it, Dermaxyl ¹.

On November 10, 2026, PubMed, the National Library of Medicine's index, held two records naming palmitoyl hexapeptide-12 in a title or abstract. Both are cited here: the laboratory study and a 2026 safety paper ⁴,⁹.

Europe PMC, an index that searches full text, listed 17 papers naming it on the same date. Four of the 17 are clinical trials of finished skin-care products, and all four are cited here ⁵,⁶,⁷,⁸.

The serums in the other three all hold this peptide among other ingredients ⁶,⁷,⁸. Two are double-blind split-face trials of one serum against its base formula after laser ⁶,⁷. The third set a peptide serum against laser ⁸.

Both split-face papers say a research fund of Yunnan Characteristic Plant Extraction Laboratory supported them, and list authors there and at Yunnan Botanee Bio-Technology Group ⁶,⁷. Both say Yunnan Botanee Co. Ltd produced the serum ⁶,⁷. The third paper's authors are at Clinique, The Estée Lauder Companies and Orentreich Medical Group, and it says they received "no specific funding" ⁸. No study cited here compares the peptide alone with a vehicle, the same product without the peptide, in people.

What are the side effects?

The Cosmetic Ingredient Review's expert panel assessed this peptide's safety in a final report released June 30, 2014 ¹. The report holds two human tests, both of Dermaxyl diluted by half ¹. In 10 adult volunteers, one 48-hour patch on the back caused no irritation ¹.

In 53 healthy adult volunteers, eight 48-hour patches and a later challenge patch caused neither irritation nor sensitization, the first step of a skin allergy ¹. A challenge patch is a last patch that tests whether the earlier ones have set up an allergy. Both tests are unpublished data submitted by the Personal Care Products Council, which also surveyed use concentrations for the report ¹. The Council calls itself "the leading national trade association representing the cosmetics and personal care products industry" ¹².

In rabbits, Biopeptide EL placed in the eye caused slight or moderate redness and swelling of the eye's lining in all three animals, for up to four days ¹. The report still classed it a non-irritant, because the scores of two of the three animals stayed below its criteria ¹. On rabbit skin it caused moderate redness that cleared within 24 or 48 hours ¹.

The report also records what it did not find. No data on reproductive or developmental toxicity, or on carcinogenicity, the ability to cause cancer, were found in the published literature for this group of peptides ¹. Its gene-damage tests were run on mixtures containing two other palmitoyl peptides ¹.

It also lists laboratory findings on cell movement and blood vessels. The sequence without its fatty acid attracted one line of mouse lung-cancer cells and not another ¹. Palmitoyl hexapeptide-12 itself enhanced blood-vessel growth in a chick-egg membrane test ¹.

The panel concluded that the group, this peptide included, is "safe in the present practices of use and concentration in cosmetics" ¹. It noted that "the low use concentrations and negative safety test data reviewed obviate any concerns" about these ingredients in cosmetic products ¹. The conclusion covers the VGVAPG sequence only ¹. The dictionary of cosmetic ingredient names gives a second possible sequence for hexapeptide-12, which the report does not address ¹. For products that are sprayed, the panel judged that incidental inhalation "would not be a significant route of exposure" ¹.

The 2026 paper, a safety framework, ran the sequence through six bioinformatics tools, computer programs and databases that assess a peptide from its sequence ⁹. One tool predicted it to be a non-toxin ⁹.

An immune database listed it as "positive in 2 B cell and 1 T cell assay related to disease exacerbation" ⁹. The authors read this as "limited immune reactivity"; B cells and T cells are immune cells, and an assay is a laboratory test ⁹. The other tools matched it to human elastin, tagged it anti-aging and chemotactic, and linked elastin to autoimmune disease ⁹. Five of the six authors work for Procter & Gamble, which the paper says "manufactures products with some of the compounds mentioned in the manuscript" ⁹.

The same paper says the panel's reports on such peptides, as a group, show that "minimal if any penetration through the skin occurs" ⁹. The 2025 study detected this peptide inside the outer layers of donated skin after eight hours under a 1 percent solution ⁴. One statement is about passage through the skin, and the other about entry into its outer layers.

In the two serum trials, five of the 51 subjects reported seven adverse events, six mild and one moderate ⁵. The paper does not say what the events were; it calls six "possibly unrelated" to the products and gives one "an unevaluable relationship" ⁵. No source cited here reports a side effect in a person that it attributes to this peptide or to a product containing it ⁴,⁹,¹,⁵,⁶,⁷,⁸.

In sport

Palmitoyl hexapeptide-12 is not named on the World Anti-Doping Agency's 2026 Prohibited List, under that name or as palmitoyl oligopeptide ¹³. No entry on the list names palmitoyl peptides or elastin fragments as a group ¹³.

What JumpstartMD offers

JumpstartMD does not prescribe palmitoyl hexapeptide-12. Our peptide library covers it so you have the facts on its FDA status and the evidence, current as of November 10, 2026.

Ready to talk?

Book FREE Consultation

Share your details and a JumpstartMD team member will reach out shortly. Or call 408.478.3496 for your free, no-obligation consultation.

Share your details and a JumpstartMD team member will reach out when we open.

Disclaimer

Compounded medications are not FDA-approved, and FDA does not review their safety, effectiveness, or quality before they are marketed. A licensed clinician decides after an evaluation whether a peptide is appropriate for you, and not every patient will qualify.